נגישות
menu      
Advanced Search
Syntax
Search...
Volcani treasures
About
Terms of use
Manage
Community:
אסיף מאגר המחקר החקלאי
Powered by ClearMash Solutions Ltd -
Effect of platelet-activating factor on coronary circulation of the domestic pig
Year:
1984
Authors :
Ezra, David
;
.
Volume :
15
Co-Authors:
Feuerstein, G., Neurobiology Research Unit, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, United States
Boyd, L.M., Neurobiology Research Unit, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, United States
Ezra, D., Neurobiology Research Unit, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, United States
Goldstein, R.E., Neurobiology Research Unit, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, United States
Facilitators :
From page:
To page:
(
Total pages:
1
)
Abstract:
The platelet-activating factor released by white blood cells and platelets has been shown to be 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine (AGEPC). To fully understand the cardiovascular actions of this substance, we examined the effects of AGEPC on coronary blood flow (CBF) and other hemodynamic parameters in anesthetized open-chest domestic pigs. Mean arterial blood pressure (MBP), electrocardiogram, heart rate (HR), left ventricular pressure, and CBF were continuously recorded. AGEPC was injected (bolus, 0.1 ml) into the left anterior descending coronary artery at increasing doses of 0.03-10 nmol. Intracoronary AGEPC produced biphasic changes in CBF: a dose-dependent increase in CBF (up to 50%) followed by a decrease (up to 92%) in CBF. The changes in CBF were not directly related to any systemic effect, although MBP was reduced consistently after a dose higher than 1 nmol of AGEPC. The increase in CBF produced by AGEPC was not affected by pretreatment with indomethacin (6 mg/kg) or FPL 55712 (1 or 3 mg), an inhibitor of slow-reacting substance of anaphylaxis (SRS-A). The decrease in CBF produced by AGEPC was attenuated by FPL 55712 and blocked by indomethacin. These data suggest that AGEPC release from aggregating platelets might play a major role in modulating CBF and cardiac function in states involving platelet-coronary interaction.
Note:
Related Files :
animal experiment
Show More
Related Content
More details
DOI :
Article number:
Affiliations:
Database:
Scopus
Publication Type:
Language:
English
Editors' remarks:
ID:
32251
Last updated date:
02/03/2022 17:27
Creation date:
17/04/2018 01:08
Scientific Publication
Effect of platelet-activating factor on coronary circulation of the domestic pig
15
Feuerstein, G., Neurobiology Research Unit, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, United States
Boyd, L.M., Neurobiology Research Unit, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, United States
Ezra, D., Neurobiology Research Unit, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, United States
Goldstein, R.E., Neurobiology Research Unit, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, United States
Effect of platelet-activating factor on coronary circulation of the domestic pig
The platelet-activating factor released by white blood cells and platelets has been shown to be 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine (AGEPC). To fully understand the cardiovascular actions of this substance, we examined the effects of AGEPC on coronary blood flow (CBF) and other hemodynamic parameters in anesthetized open-chest domestic pigs. Mean arterial blood pressure (MBP), electrocardiogram, heart rate (HR), left ventricular pressure, and CBF were continuously recorded. AGEPC was injected (bolus, 0.1 ml) into the left anterior descending coronary artery at increasing doses of 0.03-10 nmol. Intracoronary AGEPC produced biphasic changes in CBF: a dose-dependent increase in CBF (up to 50%) followed by a decrease (up to 92%) in CBF. The changes in CBF were not directly related to any systemic effect, although MBP was reduced consistently after a dose higher than 1 nmol of AGEPC. The increase in CBF produced by AGEPC was not affected by pretreatment with indomethacin (6 mg/kg) or FPL 55712 (1 or 3 mg), an inhibitor of slow-reacting substance of anaphylaxis (SRS-A). The decrease in CBF produced by AGEPC was attenuated by FPL 55712 and blocked by indomethacin. These data suggest that AGEPC release from aggregating platelets might play a major role in modulating CBF and cardiac function in states involving platelet-coronary interaction.
Scientific Publication
You may also be interested in